X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
index medicus (10) 10
male (9) 9
middle aged (9) 9
aged (7) 7
female (7) 7
life sciences (7) 7
lung cancer (6) 6
cancer (4) 4
radiology, nuclear medicine & medical imaging (4) 4
adult (3) 3
carcinoma, non-small-cell lung - diagnostic imaging (3) 3
cardiac & cardiovascular systems (3) 3
hypoxia (3) 3
lung neoplasms - diagnostic imaging (3) 3
nuclear medicine (3) 3
oncology (3) 3
positron emission tomography (3) 3
radiation therapy (3) 3
reproducibility of results (3) 3
survival (3) 3
treatment outcome (3) 3
[ sdv ] life sciences [q-bio] (2) 2
[sdv.can]life sciences [q-bio]/cancer (2) 2
[sdv]life sciences [q-bio] (2) 2
cancer therapies (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - metabolism (2) 2
cardiology (2) 2
clinical trials (2) 2
comparative analysis (2) 2
disease (2) 2
disease-free survival (2) 2
erlotinib hydrochloride (2) 2
f-misonidasole (2) 2
fluoro-deoxy-d-glucose (2) 2
hdl (2) 2
hepatocellular carcinoma (2) 2
impact (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - metabolism (2) 2
medical imaging (2) 2
medical prognosis (2) 2
medical treatment (2) 2
medicine (2) 2
misonidazole - analogs & derivatives (2) 2
misonidazole - pharmacokinetics (2) 2
non-small cell lung carcinoma (2) 2
observer variation (2) 2
original research (2) 2
patients (2) 2
positron-emission tomography (2) 2
prognosis (2) 2
radiopharmaceuticals - pharmacokinetics (2) 2
radiotherapy dose (2) 2
risk factors (2) 2
sensitivity and specificity (2) 2
standardized uptake value (2) 2
survival rate (2) 2
therapy (2) 2
time factors (2) 2
transarterial chemoembolization (2) 2
12-lead electrocardiogram (1) 1
2nd-line treatment (1) 1
[ 18 f]fdg uptake (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[ sdv.mhep.csc ] life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
[18f]fdg uptake (1) 1
[f-18]fdg uptake (1) 1
[sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
[sdv.neu]life sciences [q-bio]/neurons and cognition [q-bio.nc] (1) 1
acquisition time (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - secondary (1) 1
administration, oral (1) 1
adrenal gland neoplasms - drug therapy (1) 1
adrenal gland neoplasms - genetics (1) 1
adrenal gland neoplasms - secondary (1) 1
aged, 80 and over (1) 1
agreement (1) 1
algorithms (1) 1
alzheimer's disease (1) 1
amyloid (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
apolipoproteins (1) 1
atp synthase (1) 1
atpase (1) 1
beta-chain (1) 1
biological markers (1) 1
biology (1) 1
biomarker (1) 1
biomarkers (1) 1
biomarkers - blood (1) 1
blood-flow (1) 1
brachytherapy - methods (1) 1
breast cancer (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Vilgrain, Valérie and Pereira, Helena and Assenat, Eric and Guiu, Boris and Ilonca, Alina Diana and Ilonca, Alina D and Pageaux, Georges-Philippe and Sibert, Annie and Bouattour, Mohamed and Lebtahi, Rachida and Allaham, Wassim and Barraud, Hélène and Laurent, Valérie and Mathias, Elodie and Bronowicki, Jean-Pierre and Tasu, Jean-Pierre and Perdrisot, Rémy and Silvain, Christine and Gerolami, René and Mundler, Olivier and Seitz, Jean-Francois and Vidal, Vincent and Aubé, Christophe and Oberti, Frédéric and Couturier, Olivier and Brenot-Rossi, Isabelle and Raoul, Jean-Luc and Sarran, Anthony and Costentin, Charlotte and Itti, Emmanuel and Luciani, Alain and Adam, René and Lewin, Maïté and Samuel, Didier and Ronot, Maxime and Dinut, Aurelia and Castera, Laurent and Chatellier, Gilles and Delhom - Christol, Elisabeth and Lonjon, Julie and Abdel-Rehim, Mohamed and Dieudonné, Arnaud and Bazin, Christophe and Chagneau-Derrode, Carine and Borentain, Patrick and Bouvier, Antoine and Vervueren, Laurent and Chalaye, Julia and Kobeiter, Hicham and Edeline, Julien and Garin, Etienne and Rolland, Yan and Archambeaud, Isabelle and Eugene, Thomas and Frampas, Eric and Cassinotto, Christophe and Guyot, Martine and Hiriart, Jean-Baptiste and Lapuyade, Bruno and Vergniol, Julien and Bachellier, Philippe and Detour, Julien and Duclos, Bernard and Greget, Michel and Habersetzer, Francois and Imperiale, Alessio and Merle, Philippe and Rode, Agnès and Morvan, Julie and Nguyen-Khac, Eric and Yzet, Thierry and Baudin, Guillaume and Chevallier, Patrick and Mahamat, Abakar and Piche, Thierry and Razzouk, Micheline and Hillon, Patrick and Loffroy, Romaric and Toubeau, Michel and Vincent, Julie and Barabino, Gabriele and Bouarioua, Nadia and Cuilleron, Muriel and Ecochard, Marie and Prevot-Bitot, Nathalie and Leroy, Vincent and Roux, Julie and Sengel, Christian and Bourcier, Valérie and Ganne-Carrie, Nathalie and Seror, Olivier and Costo, Sylvie and Dao, Thông and Pelage, Jean-Pierre and Dumortier, Jérôme and Giammarile, Francesco and Valette, Pierre-Jean and Ghazzar, Nadia and Pellerin, Olivier and Taieb, Julien and ... and SARAH Trial Grp and SARAH Trial Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1624 - 1636
Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of... 
SURVIVAL | THERAPY | ONCOLOGY | COMPETING RISK | TRANSARTERIAL CHEMOEMBOLIZATION | RADIOEMBOLIZATION | QUALITY-OF-LIFE | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Microspheres | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Neoplasm Invasiveness - pathology | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Yttrium Radioisotopes - therapeutic use | Radiotherapy Dosage | Drug Administration Schedule | Administration, Oral | Brachytherapy - methods | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Carcinoma, Hepatocellular - radiotherapy | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Liver Neoplasms - radiotherapy | Sorafenib | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging | Rare earth metals | Antimitotic agents | Product development | Hepatoma | Comparative analysis | Radiotherapy | Antineoplastic agents | Life Sciences | Liver Neoplasms/drug therapy | Phenylurea Compounds/administration & dosage | Yttrium Radioisotopes/therapeutic use | Niacinamide/analogs & derivatives | Carcinoma, Hepatocellular/radiotherapy | Carcinoma, Hepatocellular/drug therapy | Cancer
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2014, Volume 9, Issue 2, p. e87629
Purpose: The aim of this prospective study was to evaluate whether [F-18]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor... 
FDG-PET | MULTICENTER | RESPONSIVENESS | FLARE | F-18-FDG PET/CT | NSCLC | MULTIDISCIPLINARY SCIENCES | 2ND-LINE TREATMENT | OPEN-LABEL | STANDARDIZED UPTAKE VALUE | CHEMOTHERAPY | Erlotinib Hydrochloride | Fluorodeoxyglucose F18 - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Survival Rate | Positron-Emission Tomography | Carcinoma, Non-Small-Cell Lung - mortality | Radiography | Radiopharmaceuticals - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Time Factors | Adult | Female | Lung Neoplasms - diagnostic imaging | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - drug therapy | Medical research | PET imaging | Erlotinib | Medicine, Experimental | Lung cancer, Small cell | Development and progression | Lung cancer, Non-small cell | Therapy | Medical imaging | Cell survival | Disease | Lung cancer | Medical treatment | Positron emission | Non-small cell lung carcinoma | Breast cancer | Criteria | Cancer therapies | Patients | Survival | Chemotherapy | Epidermal growth factor | Computed tomography | Medical prognosis | Morphology | Predictions | Tomography | Mutation | Positron emission tomography | Cancer
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 06/2013, Volume 12, Issue 1, pp. 84 - 84
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 11/2015, Volume 132, Issue Suppl_3 Suppl 3, pp. A18834 - A18834
IntroductionHigh-density lipoprotein cholesterol (HDL-C) may not be the best clinical measure of HDL for assessing cardiovascular risk. Serum inhibitor factor... 
Journal Article
Journal Article
Journal Article
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, ISSN 0161-5505, 07/2017, Volume 58, Issue 7, pp. 1045 - 1053
Journal Article
by Kobayashi, J and Yoshida, M and Tarui, S and Hirata, M and Takahashi, K and Naruse, K and Kasahara, S and Sano, S and Oh, H and Halbach, M and Peinkofer, G and Baumgartner, S and Krausgrill, B and Fatima, A and Hescheler, J and Saric, T and Mueller-Ehmsen, J and Kamakura, T and Makiyama, T and Sasaki, K and Hattori, T and Ohno, S and Yoshida, Y and Horie, M and Kimura, T and Guan, K and Streckfuss-Boemeke, K and Wolf, F and Azizian, A and Stauske, M and Tiburcy, M and Wagner, S and Maier, L. S and Zimmermann, W. H and Hasenfuss, G and Mehta, A and Sequiera, G. L and Sudibyo, Y and Jun, L and Wong, P and Liew, R and Shim, W and Dambrot, C and Braam, S. R and Freund, C. M. A. H and Van De Pas, S and Ward-Van Oostwaard, D and Atsma, D. E and Mummery, C. L and Shigeta, T and Kureishi Bando, Y and Aoyama, M and Monji, A and Mitsui, T and Cheng, X. W and Murohara, T and Saikawa, T and Nishio, S and Takahashi, N and Thuc, L. C and Saito, S and Fukui, A and Kume, O and Hara, M and Nakagawa, M and Teshima, Y and Radovits, T and Olah, A and Nemeth, B and Hidi, L and Birtalan, E and Kokeny, G and Szabo, G and Merkely, B and Rottlaender, D and Wolny, M and Motloch, L. J and Gebing, T and Reda, S and Hoppe, U. C and Feijoo-Bandin, S and Rodriguez-Penas, D and Garcia-Rua, V and Otero, M. F and Mosquera-Leal, A and Gonzalez-Juanatey, J. R and Lago, M. F and Dimitriadis, K and Tsioufis, C and Tsiachris, D and Kasiakogias, A and Psaltopoulou, T and Tzamou, V and Mazaraki, A and Andrikou, I and Pitsavos, C and Stefanadis, C and Mill, J. G and Rodrigues, S. L and Baldo, M. P and ... and on behalf of IRTG - 1566 PROMISE and on behalf of The SAVIOR investigators and on behalf of On behalf of the PLATelet inhibition and patient Outcomes (PLATO) investigators and on behalf of EPES Acute Cardiac Care group and on behalf of WHICH? Trial Investigators and on behalf of Prof. Geibel. PD Dr. Harloff, Dr. Guenther and on behalf of Italian ClinicalService Project and on behalf of PL-ACS Invaestigators and on behalf of EmbraceAC Study Group and on behalf of CHFN and on behalf of The interventional working group of the lebanese society of cardiology and on behalf of SAFETY Investigators and on behalf of grant of IGA Ministry of health of the Czech Republic no. NS9824-4/2008 and on behalf of the Korean Hypertension Research Network and on behalf of Jian-Jun Li and on behalf of the FRANCE2 steering Committee and on behalf of Cardiology&Development and on behalf of St. Antonius center for platelet function research and on behalf of the MANTRA Study investigators and on behalf of ROCKET AF Executive Committee and on behalf of Tako tsubo Italian Network and on behalf of the AF meta-analysis team and on behalf of Ibaraki Coronary Artery Disease Study (ICAS) registry and on behalf of ICALOR and on behalf of MANTRA Study Investigators and on behalf of Competence Network Heart Failure Germany and on behalf of APPRAISE-2 Study Group and on behalf of Sapaldia Study Group and on behalf of CHF-HOT Study and on behalf of CAPIRE Investigators and on behalf of Francesco Barilla, et al and on behalf of VIDA-IC investigators and on behalf of The BETTER-CARE Study Investigators and on behalf of BMIR and on behalf of The International Registry of Acute Aortic Dissection (IRAD) and on behalf of Francesca Frexia and on behalf of VIDA IC investigators and on behalf of FAST-MI 2010 and on behalf of Hypersleep and on behalf of ACTION and on behalf of SHIFT echostudy and on behalf of Korea Acute Myocardial Infarction Registry and on behalf of Barbanza investigators and on behalf of The GARFIELD Investigators and on behalf of the CHOICE trial investigators and on behalf of NIPPON DATA80/90 Research Group and on behalf of MINAP Steering Group and on behalf of PROTECT investigators and on behalf of TuePic and on behalf of Center for Clinical Heart Research, Oslo University Hospital, Ullevaal and on behalf of PROTECTION IV investigators and on behalf of ASAP Investigators and on behalf of FP7 project and on behalf of GARFIELD Investigators and on behalf of LIPID study investigators and on behalf of NIPPON DATA 80 Research Group and on behalf of COACH and on behalf of INH and on behalf of CARDIO-ARSIF registry and on behalf of Hopital Cardiologique, CIC a thematique cardiovasculaire CIC-005 INSERM, Universite Victor Segalen, CHU de Bordeaux, Bordeaux, France and on behalf of Registry of Cardiovascular Interventions, Czech Republic and on behalf of INPETU and on behalf of The International Registry of Acute Aortic Dissection and on behalf of the FAST-MI 2010 investigators and on behalf of PL-ACS Invastigators and on behalf of The Austrian Acute PCI Investigators and on behalf of Competence Network Heart Failure and on behalf of Thyroid Studies Collaboration and on behalf of University Centre for Cardiovascular Science and on behalf of SCAAR-registry and on behalf of BASKET/BASKET-PROVE Investigators and on behalf of Cardiac and on behalf of on behalf of the German Competence Network Heart Failure and the German Competence Network for HIV/AIDS and on behalf of Northern Iwate Heart Disease Registry Consortium and on behalf of J-MELODIC Investigators and on behalf of nil and on behalf of German Competence Network Heart Failure and on behalf of ARISTOTLE Investigators and on behalf of NA and on behalf of Popovici M
European Heart Journal, ISSN 0195-668X, 08/2012, Volume 33, Issue suppl 1, pp. 19 - 338
Journal Article